Search

Meeting Report: European School of Haematology International Conference of Haematological Disorders in the Elderly

The meeting started by reviewing demographic aspects, physiological changes encountered in the elderly, as well as the definition of older and elderly people, frailty and comorbidity.

Read more

Meet Robin Foà, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
I have been a member of EHA from its beginning and have participated in all EHA Congresses.

Read more

Meet Robin Foà, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
I have been a member of EHA from its beginning and have participated in all EHA Congresses.

Read more

Application forms

The deadline for the EHA Corporate Sponsor application is September 6, 2024, at 13:00 (CEST). Interested in becoming an EHA sponsor? Below you will find all the application forms for all the available EHA Sponsor Programs.

Read more

EU funding calls for hematology

Horizon Europe
European partnership for pandemic preparedness (November 26, 2024)
Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD) (deadline: November 26, 2024)
MSCA Doctoral Networks 2024 (deadline: November 27, 2024)
MSCA…

Read more

Hematology Tutorial in Sri Lanka updates expertise on myeloid malignancies and MDS of local hematologists

After a successful first edition in 2017, EHA and the Sri Lanka College of Haematologists (SLCH) organized its second two-day tutorial together in February in Colombo. The tutorial aimed to update the expertise of local hematologists from all levels.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more